Johannes Weller - Concepedia

Author

Johannes Weller

Also Known As

J M Weller, J Weller, J. M. Weller, J. Weller, J.M. Weller, Johannes M Weller, Johannes M. Weller, Johannes Weller, Johannes Weller, MD, Katharina Gruber

144

Publications

Citations

H-Index

Concepts

All Affiliations

University Hospital Bonn Goethe University Frankfurt Heidelberg University University of Cologne Johanniter-Krankenhaus Bonn

About

Johannes Weller is an author at University Hospital Bonn specializing in medicine, glioma, and high-grade gliomas.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.1K
2	Neurology	4	4	1K
3	Health Sciences	3	3	621
4	Public Health	1	1	394
5	Emergency Medicine	1	1	394

Johannes Weller

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, The Lancet Hematological MalignancyNeuro-oncologyTreatment StrategiesMedicineStandard Temozolomide Therapy	2019	556
Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial Martin Bendszus, Jens Fiehler, Fabien Subtil, The Lancet ThrombosisEndovascular ThrombectomyEndovascular TechniqueIschemic StrokeCardiovascular Disease	2023	394
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors Émilie Le Rhun, Patrick Devos, Johannes Weller, Neuro-Oncology	2020	112
Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival Matthias Schneider, Anna‐Laura Potthoff, Elisa Scharnböck, Journal of Neuro-Oncology	2020	53
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial Götz Thomalla, Jens Fiehler, Fabien Subtil, The Lancet Neurology	2024	52
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial Johannes Weller, Theophilos Tzaridis, Frederic Mack, The Lancet Oncology Neuro-oncologyTreatment StrategiesNeurological AssessmentCognitive PerformanceHealth-related Quality	2019	43
Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection Matthias Schneider, Anna‐Laura Potthoff, Vera C. Keil, Journal of Neuro-Oncology Neuro-oncologySurgical OncologyTemporal GlioblastomaSurgeryHigh-grade Gliomas	2019	42
Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis Motaz Hamed, Niklas Schäfer, Christian Bode, Frontiers in Oncology	2021	40
The patients’ perspective on the burden of idiopathic intracranial hypertension Max Witry, Christine Kindler, Johannes Weller, The Journal of Headache and Pain	2021	37
Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET Jan‐Michael Werner, Johannes Weller, Garry Ceccon, Clinical Cancer Research	2021	36

Page 1